Biora Therapeutics Inc   (BIOR)
Other Ticker:  
Price: $0.6210 $0.00 0.161%
Day's High: $0.65 Week Perf: -11.16 %
Day's Low: $ 0.61 30 Day Perf: -46 %
Volume (M): 244 52 Wk High: $ 6.70
Volume (M$): $ 152 52 Wk Avg: $2.28
Open: $0.61 52 Wk Low: $0.61

 Market Capitalization (Millions $) 9
 Shares Outstanding (Millions) 15
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -122
 Cash Flow (TTM) (Millions $) -24
 Capital Exp. (TTM) (Millions $) 0

Biora Therapeutics Inc
Biora Therapeutics Inc is a biotechnology company that specializes in developing innovative solutions for the treatment of chronic wounds. The company was founded in 1994 and is based in Malmo, Sweden. It has a global presence with offices in Europe, North America, and Asia.

The main focus of Biora Therapeutics is to develop bioactive materials that can stimulate and enhance the natural healing process of chronic wounds. These materials are designed to work in synergy with the body's own immune system and promote tissue repair and regeneration.

The company has developed several proprietary technologies that are based on the use of growth factors, collagen matrices, and other biomaterials. These technologies are designed to deliver an optimized combination of growth factors and other bioactive molecules to chronic wounds, thereby promoting faster healing and reducing the risk of infection.

Biora Therapeutics has a range of products that are used in the treatment of chronic wounds, including diabetic foot ulcers, venous ulcers, pressure ulcers, and burn injuries. The company's flagship product is Purion, a patented collagen matrix that contains a specific combination of growth factors and antimicrobial peptides. Purion is designed to stimulate wound healing while also reducing the risk of infection.

In addition to Purion, Biora Therapeutics has also developed a range of other products, including wound dressings, wound care kits, and topical gels. These products are aimed at meeting the needs of patients across a wide range of wound types and severities.

The company has a strong commitment to research and development, and invests heavily in innovative technologies and new therapeutic approaches. Biora Therapeutics works closely with leading academic and clinical research institutions to gather evidence-based data on the efficacy and safety of its products.

Overall, Biora Therapeutics is a leading innovator in the field of wound care, and its products have been shown to deliver significant benefits to patients with chronic wounds. With its strong focus on research and development, the company is well positioned to continue driving advances in this important area of healthcare.

   Company Address: 4330 La Jolla Village Drive San Diego 92122 CA
   Company Phone Number: 727-2841   Stock Exchange / Ticker: NASDAQ BIOR


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Clinical Study

BT-600: Clinically Validating the Promise of Precision Medicine - An Exploration into Biora Therapeutics' NaviCap Platform's Success

Published Thu, Apr 4 2024 12:00 PM UTC

The dawn of a new age in therapeutic management has arrived, as the imminent rise of promising treatments, both in terms of effectiveness and safety, continues to redefine the horizons of our knowledge in medicine. Biora Therapeutics has taken a giant leap in this evolutionary journey of treatment advances, with interim positive clinical trial results of its drug candidate, ...

Financing Agreement

Biora Therapeutics Secures $6 Million in Offering as Athyrium Capital Management Demonstrates Confidence in Biotech Sector.

Published Wed, Apr 3 2024 8:05 PM UTC

Biora Therapeutics Closes $6 Million Offering as Athyrium Capital Management Demonstrates Confidence in Equity Holdings
SAN DIEGO, April 3, 2024 ?? Biora Therapeutics, Inc. (Nasdaq: BIOR), a biotech company focused on revolutionizing therapeutic delivery, announced the successful completion of a registered direct offering and concurrent private placement, raising a total...


Biora Therapeutics Achieves Financial Reinforcement as Athyrium Capital Bolsters Equity Exposure

Published Mon, Apr 1 2024 12:01 PM UTC

In a recent press release, Biora Therapeutics announced significant developments in its capital structure. The company has successfully finalized definitive agreements for the purchase and sale of 5,454,548 common stock shares. Alongside this, Biora Therapeutics also revealed its debt reduction strategy, while its largest shareholder, Athyrium Capital Management, h...

Financing Agreement

Biora Therapeutics Excels in Reducing Net Debt and Capitalizes on Legacy Asset Monetization for Financial Growth.

Published Mon, Mar 11 2024 12:01 PM UTC

Biora Therapeutics Further Reduces Net Debt and Monetizes Legacy Asset
In a significant development, Biora Therapeutics Inc, a leading pharmaceutical company, has successfully generated $3 million in nondilutive capital through the monetization of a legacy asset. Additionally, the company has exchanged notes resulting in a further $2.8 million in capital, effectively red...

Clinical Study

Assessing the Successful Completion of BT-600 Single-Ascending Dose Cohorts and its Implications for Biora Therapeutics' Drug-Device Combination

Published Mon, Feb 26 2024 1:01 PM UTC

In the pharmaceutical industry, the successful completion of clinical trials is a crucial milestone that marks the progress of a potential therapeutic candidate. This article aims to interpret two key announcements made by Biora Therapeutics regarding the Phase 1 clinical study of their drug-device combination, BT-600. We will outline the facts presented in the articles and ...



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com